Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) ROCE %: 15.84% (As of Mar. 2026)


SHSE:600276 Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
86 GF Score
Price ¥52.93
GF Value ¥60.34
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co ROCE %?

Jiangsu Hengrui Pharmaceuticals Co SHSE:600276 +8.75% 86 ROCE % is 15.84% as of Mar. 2026. GuruFocus rates SHSE:600276 with a GF Score™ of 86/100 and a GF Value™ of ¥60.34 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jiangsu Hengrui Pharmaceuticals Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 15.84%.

Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jiangsu Hengrui Pharmaceuticals Co ROCE % Related Terms

Jiangsu Hengrui Pharmaceuticals Co ROCE % Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co ROCE % Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.38 10.66 11.69 16.36 15.86

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.68 22.18 9.09 14.83 15.84
SHSE:600276
86GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co ROCE % Calculation

Jiangsu Hengrui Pharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=8721.975/( ( (50135.645 - 3633.596) + (69867.316 - 6369.237) )/ 2 )
=8721.975/( (46502.049+63498.079)/ 2 )
=8721.975/55000.064
=15.86 %

Jiangsu Hengrui Pharmaceuticals Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=10229.24/( ( (69867.316 - 6369.237) + (71293.862 - 5636.724) )/ 2 )
=10229.24/( ( 63498.079 + 65657.138 )/ 2 )
=10229.24/64577.6085
=15.84 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.84% mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a ROCE % of 15.84% as of Mar. 2026.
Is Jiangsu Hengrui Pharmaceuticals Co's ROCE % too high?
Jiangsu Hengrui Pharmaceuticals Co's current ROCE % is 15.84%. The Drug Manufacturers industry median ROCE % is 7.01. Jiangsu Hengrui Pharmaceuticals Co's value of 15.84% is 126% above this industry median. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's ROCE % compare to ZTS and UTHR?
Jiangsu Hengrui Pharmaceuticals Co's ROCE % of 15.84% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Jiangsu Hengrui Pharmaceuticals Co's value of 15.84% is 126% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current ROCE % of 15.84% is 126% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current ROCE % is 15.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥52.93 — trading 12.3% below its estimated fair value. The current ROCE % is 15.84% and 126% above the Drug Manufacturers industry median of 7.01. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current ROCE % is 15.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥52.93 is trading 12.3% below its estimated GF Value™ of ¥60.34. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for SHSE:600276:

  • ROCE %: 15.84%
  • GF Value™: ¥60.34 vs. price of ¥52.93 (12.3% below fair value)
  • GF Score™: 86/100 with 1 warning sign
  • Industry Position: 126% above the Drug Manufacturers median

No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score

Get the complete analysis for SHSE:600276

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥52.93
Price
¥60.34
GF Value